Patents by Inventor Elaine Tuomanen
Elaine Tuomanen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11684664Abstract: Compositions nod methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections. Compositions provided herein comprise a variety immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing die various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or acytolysoid polypeptide, or an active variant or fragment thereof.Type: GrantFiled: April 16, 2020Date of Patent: June 27, 2023Assignee: St. Jude Children's Research HospitalInventors: Elaine Tuomanen, Elizabeth R. Mann
-
Publication number: 20200246447Abstract: Compositions nod methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections. Compositions provided herein comprise a variety immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing die various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or acytolysoid polypeptide, or an active variant or fragment thereof.Type: ApplicationFiled: April 16, 2020Publication date: August 6, 2020Inventors: Elaine Tuomanen, Elizabeth R. Mann
-
Patent number: 10632183Abstract: Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof.Type: GrantFiled: November 14, 2017Date of Patent: April 28, 2020Assignee: ST. JUDE CHILDRENS RESEARCH HOSPITALInventors: Elaine Tuomanen, Elizabeth R. Mann
-
Publication number: 20180078633Abstract: Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof.Type: ApplicationFiled: November 14, 2017Publication date: March 22, 2018Applicant: St. Jude Children's Research HospitalInventors: Elaine Tuomanen, Elizabeth R. Mann
-
Patent number: 9844587Abstract: Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof.Type: GrantFiled: October 7, 2015Date of Patent: December 19, 2017Assignee: St. Jude Children's Research HospitalInventors: Elaine Tuomanen, Elizabeth R. Mann
-
Patent number: 9249199Abstract: Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R21 or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope.Type: GrantFiled: March 20, 2014Date of Patent: February 2, 2016Assignee: St. Jude Children's Research HospitalInventors: Karim C. El Kasmi, Brad Jordan, Richard Kriwacki, Beth Mann, Carlos J. Orihuela, Elaine Tuomanen
-
Publication number: 20160022799Abstract: Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumo-coccal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one poly-peptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof.Type: ApplicationFiled: October 7, 2015Publication date: January 28, 2016Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Elaine Tuomanen, Elizabeth R. Mann
-
Patent number: 9181308Abstract: Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof.Type: GrantFiled: March 23, 2012Date of Patent: November 10, 2015Assignee: St. Jude Children's Research HospitalInventors: Elaine Tuomanen, Elizabeth R. Mann
-
Publication number: 20140248303Abstract: Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R21 or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope.Type: ApplicationFiled: March 20, 2014Publication date: September 4, 2014Applicant: St. Jude Children's Research HospitalInventors: Karim C. El Kasmi, Brad Jordan, Richard Kriwacki, Beth Mann, Carlos J. Orihuela, Elaine Tuomanen
-
Patent number: 8722055Abstract: Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R2i or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope.Type: GrantFiled: September 26, 2007Date of Patent: May 13, 2014Assignee: St. Jude Children's Research HospitalInventors: Karim C. El Kasmi, Brad Jordan, Richard Kriwacki, Beth Mann, Carlos J. Orihuela, Elaine Tuomanen
-
Publication number: 20140023674Abstract: Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof.Type: ApplicationFiled: March 23, 2012Publication date: January 23, 2014Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Elaine Tuomanen, Elizabeth R. Mann
-
Publication number: 20100143394Abstract: Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R2i or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope.Type: ApplicationFiled: September 26, 2007Publication date: June 10, 2010Applicant: St. Jude Children's Research HospitalInventors: Karim C. El Kasmi, Brad Jordan, Richard Kriwacki, Beth Mann, Carlos J. Orihuela, Elaine Tuomanen
-
Patent number: 7425327Abstract: The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.Type: GrantFiled: July 28, 2004Date of Patent: September 16, 2008Assignee: The Rockefeller UniversityInventors: H. Robert Masure, Carsten I. Rosenow, Elaine Tuomanen, Theresa M. Wizemann
-
Publication number: 20050208069Abstract: This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides a isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO: 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a N— terminal choline binding protein A truncate.Type: ApplicationFiled: January 10, 2005Publication date: September 22, 2005Applicants: St. Jude Children's Research Hospital, Medimmune, Inc.Inventors: Elaine Tuomanen, Theresa Wizemann, H. Masure, Leslie Johnson, Scott Koenig
-
Publication number: 20050048590Abstract: The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.Type: ApplicationFiled: July 28, 2004Publication date: March 3, 2005Inventors: H. Masure, Carsten Rosenow, Elaine Tuomanen, Theresa Wizemann
-
Patent number: 6784164Abstract: The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.Type: GrantFiled: April 9, 2001Date of Patent: August 31, 2004Assignee: The Rockefeller UniversityInventors: H. Robert Masure, Carsten I. Rosenow, Elaine Tuomanen, Theresa M. Wizemann
-
Publication number: 20030175293Abstract: The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.Type: ApplicationFiled: April 9, 2001Publication date: September 18, 2003Inventors: H. Robert Masure, Carsten I. Rosenow, Elaine Tuomanen, Theresa M. Wizemann
-
Patent number: 6245335Abstract: The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.Type: GrantFiled: May 1, 1997Date of Patent: June 12, 2001Assignee: The Rockefeller UniversityInventors: H. Robert Masure, Carsten I. Rosenow, Elaine Tuomanen, Theresa M. Wizemann
-
Patent number: 6015560Abstract: Peptides which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents are described.Type: GrantFiled: June 6, 1995Date of Patent: January 18, 2000Assignee: The Rockfeller UniversityInventors: Elaine Tuomanen, H. Robert Masure
-
Patent number: 5981229Abstract: Provided herein are novel nucleic acids which encode exported proteins of Gram positive bacteria, and the proteins encoded by such nucleic acids. Also provided are methods of producing such exported proteins, and vaccines for protecting an animal from infection with a gram positive bacterium, wherein the vaccines utilize the novel nucleic acids and proteins of the invention.Type: GrantFiled: April 10, 1996Date of Patent: November 9, 1999Assignee: The Rockefeller UniversityInventors: H. Robert Masure, Barbara J. Pearce, Elaine Tuomanen